Apogee Therapeutics, Inc. (APGE)

NASDAQ: APGE · IEX Real-Time Price · USD
46.84
-0.68 (-1.43%)
Jul 19, 2024, 10:05 AM EDT - Market open
-1.43%
Market Cap 2.74B
Revenue (ttm) n/a
Net Income (ttm) -103.55M
Shares Out 58.46M
EPS (ttm) -5.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,646
Open 47.60
Previous Close 47.52
Day's Range 46.00 - 47.60
52-Week Range 14.19 - 72.29
Beta n/a
Analysts Strong Buy
Price Target 65.80 (+40.48%)
Earnings Date Aug 26, 2024

About APGE

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended ha... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 14, 2023
Employees 9
Stock Exchange NASDAQ
Ticker Symbol APGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for APGE stock is "Strong Buy." The 12-month stock price forecast is $65.8, which is an increase of 40.48% from the latest price.

Price Target
$65.8
(40.48% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment...

7 weeks ago - GlobeNewsWire

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment...

2 months ago - GlobeNewsWire

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile

2 months ago - GlobeNewsWire

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concep...

2 months ago - GlobeNewsWire

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

SAN FRANCISCO and WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment...

2 months ago - GlobeNewsWire

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing...

4 months ago - GlobeNewsWire

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million

SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologic...

4 months ago - GlobeNewsWire

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for th...

4 months ago - GlobeNewsWire

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for th...

4 months ago - GlobeNewsWire

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher exposures leading to poten...

4 months ago - GlobeNewsWire

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc

Pharmacokinetic data support potential best-in-class profile with potential for improved clinical responses from greater exposures in induction than currently available biologic therapies and maintena...

4 months ago - GlobeNewsWire

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatme...

4 months ago - GlobeNewsWire

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatmen...

7 months ago - GlobeNewsWire

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers expected ...

8 months ago - GlobeNewsWire

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatmen...

9 months ago - GlobeNewsWire

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the tre...

10 months ago - GlobeNewsWire

Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day

SAN FRANCISCO and WALTHAM, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatme...

11 months ago - GlobeNewsWire

Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics

Lead program, APG777, a novel subcutaneous half-life extended anti-IL-13 antibody, discovered by Paragon, enters first-in-human clinical trial Apogee Therapeutics' recently announced upsized IPO furth...

11 months ago - PRNewsWire

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical trial initiated and first participant dosed ahead of schedule for lead produc...

11 months ago - GlobeNewsWire

Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board

SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatmen...

11 months ago - GlobeNewsWire

Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care, including the potential for every two- or three-month dosing

1 year ago - GlobeNewsWire

Apogee Therapeutics to Participate in Upcoming August Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic der...

1 year ago - GlobeNewsWire

Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO and WALTHAM, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic der...

1 year ago - GlobeNewsWire

Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering

SAN FRANCISCO and WALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic der...

1 year ago - GlobeNewsWire

Apogee Therapeutics sets IPO terms, to be valued at up to $774.5 mln

Apogee Therapeutics Inc. APGE, has set terms for its initial public offering, as the Massachusetts-based biotechnology company developing treatments for chronic obstructive pulmonary disease (COPD) lo...

1 year ago - Market Watch